Mohammad O. Ramadan, MD, discusses the importance of genetic testing for prostate cancer screening, diagnosis, and treatment. He notes that there is currently a professional practice gap in this area, even as genetic testing becomes more widely available. Studies suggest that approximately 17% of prostate cancer patients are biomarker positive, and therefore may benefit more than other patients from treatments like PARP inhibitors. Research like this has led the NCCN to recommend germline genetic testing for all men with high-risk, very-high-risk, regional, or metastatic prostate cancer. With this guideline in place, urologists will have to quickly figure out how to provide widespread testing, and may have to partner with geneticists.Read More
Mohammad O. Ramadan, MD
[types usermeta='affiliation' user_is_author='true'][/types]
[types usermeta='location' user_is_author='true'][/types]
Dr. Mohammad Ramadan is a board-certified urologist who completed a fellowship in urologic oncology and minimally-invasive robotic surgery. Additionally, he completed his residency at the University of Oklahoma Health Sciences Center. Dr. Ramadan received his Doctor of Medicine from the University of Oklahoma College of Medicine after completing his Bachelor's of Mechanical Engineering at The Johns Hopkins University. Dr. Ramadan is the Urology Section Chief at the Oklahoma City Veterans Affairs Medical Center. He is focused on providing excellent urologic care to veterans especially in the areas of urologic cancers and minimally invasive surgery.